GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.
You may also be interested in...
The Good News for Biotech: New Regulation Opens A New Path to Profitability
REMS program may create new options for smaller companies targeting niche markets.
The Good News for Biotech: New Regulation Opens A New Path to Profitability
REMS program may create new options for smaller companies targeting niche markets.
Forest Teams Up With Microbia On IBS-C Agent Linaclotide
Firms plan to initiate Phase III studies in the second half of 2008.